AVBP

ArriVent BioPharma, Inc. Common Stock (AVBP) Business Model Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Model

Revenue is not provided in the fresh metrics, so the model remains difficult to assess from this update alone.

The company appears to be operating with no reported sales margin data in the current snapshot, limiting visibility into monetization quality.

Profitability

TTM profitability remains deeply negative, with return on assets at -41.5%, return on equity at -50.3%, and return on invested capital at -47.9%.

Margins are still shown at 0 across gross, operating, EBITDA, pretax, and net profit lines, indicating no demonstrated earnings power in the current data.

Balance Sheet

Liquidity is very strong, with a current ratio of 14.16x and a cash ratio of 5.56x.

Leverage remains minimal, with debt-to-equity at 0.0010 and debt-to-assets at 0.0009, while cash per share of 7.84 exceeds book value per share of 7.71.

Cash Flow

Cash flow remains negative, with operating cash flow per share at -3.11 and free cash flow per share at -3.11.

Free cash flow yield is -10.8% and operating cash flow yield is -8.2%, showing the business is still burning cash on a TTM basis.

Capital Efficiency

Capital efficiency remains poor, with operating return on assets at -47.3% and return on capital employed at -48.0%.

The company is not currently generating positive returns on invested capital, so the asset base is not yet producing attractive economic output.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ArriVent BioPharma, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →